Extracardiac Prothrombotic Effects of COVID-19

Rohan Kankaria; Cristina Sanina; Mohamed Gabr; Jose Wiley; Anna E Bortnick

doi:10.1016/j.ccl.2022.03.008

Extracardiac Prothrombotic Effects of COVID-19

Cardiol Clin. 2022 Aug;40(3):337-344. doi: 10.1016/j.ccl.2022.03.008. Epub 2022 Mar 29.

Authors

Rohan Kankaria¹, Cristina Sanina², Mohamed Gabr², Jose Wiley², Anna E Bortnick³

Affiliations

¹ Albert Einstein College of Medicine, Montefiore Medical Center, 1300 Morris Park Avenue, Bronx, NY 10461, USA.
² Albert Einstein College of Medicine, Montefiore Medical Center, 1300 Morris Park Avenue, Bronx, NY 10461, USA; Department of Medicine, Division of Cardiology, Montefiore Medical Center, 111 E 210th Street, Bronx, NY 10467 USA.
³ Albert Einstein College of Medicine, Montefiore Medical Center, 1300 Morris Park Avenue, Bronx, NY 10461, USA; Department of Medicine, Division of Cardiology, Montefiore Medical Center, 111 E 210th Street, Bronx, NY 10467 USA; Division of Geriatrics, Montefiore Medical Center, 111 E 210th Street, Bronx, NY 10467 USA. Electronic address: [email protected].

Abstract

COVID-19 infection triggers a heightened inflammatory response which in turn, increases thrombosis and thromboembolism. Microvascular thrombosis has been detected in various tissue beds which may account for some of the multi-system organ dysfunction associated with COVID-19. Additional research is needed to understand which prophylactic and therapeutic drug regimens are best for the prevention and treatment of thrombotic complications of COVID-19.

Keywords: COVID-19; Deep vein thrombosis; Myocardial infarction; Pulmonary embolism; SARS-CoV-2; Stroke; Thrombosis.

Publication types

Review

MeSH terms

Anticoagulants / therapeutic use
COVID-19* / complications
Humans
SARS-CoV-2
Thrombosis* / etiology
Thrombosis* / prevention & control

Substances

Anticoagulants

Grants and funding

K23 HL146982/HL/NHLBI NIH HHS/United States